Humira

Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Key Humira patent goes down via IPR—but biosims makers shouldn't celebrate yet, analysts warn
Fierce Pharma
Humira
patents
AbbVie
biosimilars
Flag link:
AbbVie Reports Humira Sales Growth in 1st Quarter
AbbVie Reports Humira Sales Growth in 1st Quarter
Yahoo/GuruFocus
AbbVie
Humira
earnings
Flag link:
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Eli Lilly
Inctye
AbbVie
Regeneron
rheumatoid arthritis
FDA
baricitinib
Humira
Flag link:
3 Big Biotech Stocks With Big-Time Catalysts
3 Big Biotech Stocks With Big-Time Catalysts
Motley Fool
Regeneron
Praluent
Amgen
biosimilars
Amjevita
Humira
ABP-215
Avastin
ABP-980
Herceptin
Celgene
ozanimod
Flag link:
$5B in Humira sales at stake with Amgen EU approval
$5B in Humira sales at stake with Amgen EU approval
BioPharma Dive
Humira
Amgen
Europe
rheumatoid arthritis
Amgevita
biosimiliars
Flag link:
The 19 Best-Selling Prescription Drugs of All-Time
The 19 Best-Selling Prescription Drugs of All-Time
Motley Fool
Lipitor
Humira
Seretide
Remicade
Plavix
Enbrel
Rituxan
Herceptin
Avastin
Nexium
Zyprexa
Flag link:
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Marketwatch
Pfizer
Xeljanz
AbbVie
Humira
rheumatoid arthritis
Flag link:
Amgen Gets EU Nod for Humira Biosimilar
Amgen Gets EU Nod for Humira Biosimilar
Investopedia
Amgen
Humira
biosimilars
ABP 501
Flag link:
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Yahoo/GuruFocus
Boehringer Ingelheim
Humira
biosimilars
FDA
EMA
BI 695501
AbbVie
Flag link:
3 Biggest Risks for AbbVie in 2017
3 Biggest Risks for AbbVie in 2017
Motley Fool
AbbVie
Humira
biosimilars
Imbruvica
Viekira Pak
Elagolix
risankizumab
Flag link:
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
Fierce Pharma
Humira
AbbVie
biosimilars
ASH
Flag link:
AbbVie's Humira a Step Closer to Approval in Europe
AbbVie's Humira a Step Closer to Approval in Europe
Yahoo/GuruFocus
AbbVie
Humira
Europe
Flag link:
J&J, GSK stumble coming out of the gate with mixed PhIII rheumatoid arthritis data for sirukumab
J&J, GSK stumble coming out of the gate with mixed PhIII rheumatoid arthritis data for sirukumab
Endpoints
JNJ
GSK
rheumatoid arthritis
sirukumab
AbbVie
Humira
Flag link:
AbbVie: Take That Coherus!
AbbVie: Take That Coherus!
Barron's
AbbVie
Coherus Biosciences
Humira
biosimilars
Flag link:
In October TV pharma ad spending, AbbVie's Humira and Pfizer's Lyrica continue to dominate
In October TV pharma ad spending, AbbVie's Humira and Pfizer's Lyrica continue to dominate
Fierce Pharma
drug ads
AbbVie
Humira
Pfizer
Lyrica
Flag link:
3 Things AbbVie's Management Said While Its Stock Got Hammered
3 Things AbbVie's Management Said While Its Stock Got Hammered
Motley Fool
AbbVie
earnings
Humira
Imbruvica
Viekira Pak
Flag link:
FDA approval could be delayed for Sanofi Genzyme’s next blockbuster
FDA approval could be delayed for Sanofi Genzyme’s next blockbuster
Bizjournals.com
FDA
Sanofi
Sanofi Genzyme
drug manufacturing
biosimilars
Humira
Sarilumab
Flag link:
Boehringer flags PhIII success for another Humira knockoff, setting up a crowded field of cheaper rivals — eventually
Boehringer flags PhIII success for another Humira knockoff, setting up a crowded field of cheaper rivals — eventually
Endpoints
Boehringer Ingelheim
Humira
BI 695501
AbbVie
rheumatoid arthritis
Flag link:
AbbVie Is Under Duress With Fierce Competition
AbbVie Is Under Duress With Fierce Competition
Seeking Alpha
AbbVie
Humira
biosimilars
Amgen
Baxalta
Shire
Flag link:
Could J&J's recent news about its rheumatoid arthritis and Crohn's disease drugs threaten AbbVie's Humira?
Could J&J's recent news about its rheumatoid arthritis and Crohn's disease drugs threaten AbbVie's Humira?
Motley Fool
JNJ
rheumatoid arthritis
Crohn's Disease
AbbVie
Humira
sirukumab
Flag link: